Details of the Drug Combination

General Information of Drug Combination (ID: DCHPYIJ)

Drug Combination Name
Mirtazapine Methamphetamine
Indication
Disease Entry Status REF
Methamphetamine Use Disorder Phase 1 [1]
Component Drugs Mirtazapine   DML53ZJ Methamphetamine   DMPM4SK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Mirtazapine
Disease Entry ICD 11 Status REF
Depression 6A70-6A7Z Approved [2]
Mirtazapine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Antagonist [6]
------------------------------------------------------------------------------------
Mirtazapine Interacts with 5 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [8]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [7]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [9]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [9]
------------------------------------------------------------------------------------
Mirtazapine Interacts with 4 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Stearoyl-CoA desaturase (SCD) OTB1073G SCD_HUMAN Increases Expression [10]
Solute carrier family 2, facilitated glucose transporter member 4 (SLC2A4) OTJZG0LD GLUT4_HUMAN Increases Expression [11]
Solute carrier family 2, facilitated glucose transporter member 5 (SLC2A5) OTZNYEKF GTR5_HUMAN Increases Expression [11]
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1) OTCO26FV HMCS1_HUMAN Increases Expression [10]
------------------------------------------------------------------------------------
Indication(s) of Methamphetamine
Disease Entry ICD 11 Status REF
Anxiety N.A. Approved [3]
Attention deficit hyperactivity disorder 6A05.Z Approved [4]
Depression 6A70-6A7Z Approved [3]
Methamphetamine dependence 6C46.2 Approved [3]
Obesity 5B81 Approved [3]
Pain MG30-MG3Z Approved [5]
Sexually transmitted infection 1A9Z Approved [3]
Substance dependence N.A. Approved [3]
Methamphetamine Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adrenergic receptor alpha-1B (ADRA1B) TTBRKXS ADA1B_HUMAN Antagonist [15]
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Agonist [5]
------------------------------------------------------------------------------------
Methamphetamine Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Vesicular amine transporter 2 (SLC18A2) DTT7VPB VMAT2_HUMAN Substrate [16]
------------------------------------------------------------------------------------
Methamphetamine Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [17]
------------------------------------------------------------------------------------
Methamphetamine Interacts with 108 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
D(2) dopamine receptor (DRD2) OTBLXKEG DRD2_HUMAN Increases Response To Substance [18]
PRKCA-binding protein (PICK1) OT8QE6EU PICK1_HUMAN Increases Response To Substance [19]
Zeta-sarcoglycan (SGCZ) OTVGTEOD SGCZ_HUMAN Affects Response To Substance [14]
Cytosolic carboxypeptidase 4 (AGBL1) OT8NQLH0 CBPC4_HUMAN Increases ADR [20]
Activator of apoptosis harakiri (HRK) OTR4GWJ0 HRK_HUMAN Increases Expression [21]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [21]
Cell division control protein 45 homolog (CDC45) OT6NNLOD CDC45_HUMAN Decreases Expression [21]
BAI1-associated protein 3 (BAIAP3) OTS1H0J0 BAIP3_HUMAN Increases Expression [21]
G2/mitotic-specific cyclin-B2 (CCNB2) OTIEXTDK CCNB2_HUMAN Decreases Expression [21]
Kinesin-like protein KIF20A (KIF20A) OTXOQHE0 KI20A_HUMAN Decreases Expression [21]
ATP-binding cassette sub-family C member 6 (ABCC6) OTZT0LKT MRP6_HUMAN Decreases Expression [21]
Keratin, type I cytoskeletal 14 (KRT14) OTUVZ1DW K1C14_HUMAN Increases Expression [21]
Fatty acid-binding protein, heart (FABP3) OT562DA1 FABPH_HUMAN Increases Expression [21]
Galanin peptides (GAL) OTB3VPTO GALA_HUMAN Increases Expression [21]
Phospholipase A2 group V (PLA2G5) OTQRSKCZ PA2G5_HUMAN Increases Expression [21]
DNA-binding protein inhibitor ID-1 (ID1) OTKGNZN5 ID1_HUMAN Decreases Expression [21]
Actin, alpha cardiac muscle 1 (ACTC1) OTJU04B1 ACTC_HUMAN Decreases Expression [21]
Origin recognition complex subunit 1 (ORC1) OTHWU8IJ ORC1_HUMAN Decreases Expression [21]
PCNA-associated factor (PCLAF) OTMVIOUU PAF15_HUMAN Decreases Expression [21]
Disks large-associated protein 5 (DLGAP5) OTWCN39U DLGP5_HUMAN Decreases Expression [21]
Centrosomal protein of 55 kDa (CEP55) OTGSG2PA CEP55_HUMAN Decreases Expression [21]
Solute carrier organic anion transporter family member 4C1 (SLCO4C1) OTVILUUN SO4C1_HUMAN Increases Expression [21]
Protein MCM10 homolog (MCM10) OTV0O3JN MCM10_HUMAN Decreases Expression [21]
Ras guanyl-releasing protein 3 (RASGRP3) OTEMEV3P GRP3_HUMAN Increases Expression [21]
Abnormal spindle-like microcephaly-associated protein (ASPM) OTKXQMNA ASPM_HUMAN Decreases Expression [21]
CD177 antigen (CD177) OTS79FNF CD177_HUMAN Increases Expression [21]
Holliday junction recognition protein (HJURP) OTWMV16B HJURP_HUMAN Decreases Expression [21]
Interferon-stimulated gene 20 kDa protein (ISG20) OTCWRJJW ISG20_HUMAN Increases Expression [21]
RAD51-associated protein 1 (RAD51AP1) OTXM7UTD R51A1_HUMAN Decreases Expression [21]
Lymphokine-activated killer T-cell-originated protein kinase (PBK) OT5Z27TW TOPK_HUMAN Decreases Expression [21]
Kinesin-like protein KIFC1 (KIFC1) OTNQDS00 KIFC1_HUMAN Decreases Expression [21]
Denticleless protein homolog (DTL) OTC29RYE DTL_HUMAN Decreases Expression [21]
Adherens junction-associated protein 1 (AJAP1) OTAAW121 AJAP1_HUMAN Increases Expression [21]
2-oxoglutarate dehydrogenase-like, mitochondrial (OGDHL) OT1AZK6R OGDHL_HUMAN Increases Expression [21]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Expression [22]
E3 ubiquitin-protein ligase parkin (PRKN) OTJBN41W PRKN_HUMAN Decreases Expression [23]
Serine/threonine-protein kinase/endoribonuclease IRE1 (ERN1) OTY9R6FZ ERN1_HUMAN Increases Phosphorylation [12]
T-cell surface glycoprotein CD3 delta chain (CD3D) OTRBLP0R CD3D_HUMAN Increases Expression [24]
Amyloid-beta precursor protein (APP) OTKFD7R4 A4_HUMAN Increases Expression [25]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Activity [26]
Synaptophysin (SYP) OTFJKMO4 SYPH_HUMAN Decreases Expression [27]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Decreases Cleavage [28]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Increases Expression [12]
Cyclic AMP-dependent transcription factor ATF-6 alpha (ATF6) OTAFHAVI ATF6A_HUMAN Increases Cleavage [12]
Troponin I, cardiac muscle (TNNI3) OT65E12V TNNI3_HUMAN Increases Expression [29]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Increases Activity [26]
D(1A) dopamine receptor (DRD1) OTLZPBT7 DRD1_HUMAN Increases Expression [30]
Solute carrier family 2, facilitated glucose transporter member 5 (SLC2A5) OTZNYEKF GTR5_HUMAN Increases Expression [31]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Affects Phosphorylation [25]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Affects Phosphorylation [25]
Sodium-dependent serotonin transporter (SLC6A4) OT6FGDLW SC6A4_HUMAN Decreases Expression [32]
D(3) dopamine receptor (DRD3) OT0OFFKB DRD3_HUMAN Decreases Expression [33]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [12]
Tuberin (TSC2) OT47LWI9 TSC2_HUMAN Increases Phosphorylation [23]
BH3-interacting domain death agonist (BID) OTOSHSHU BID_HUMAN Increases Expression [22]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Affects Localization [34]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [22]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Increases Expression [22]
Inactive caspase-12 (CASP12) OTY2W6FG CASPC_HUMAN Increases Expression [24]
Bcl-2-binding component 3, isoforms 3/4 (BBC3) OTUAXDAY BBC3B_HUMAN Increases Expression [22]
Tribbles homolog 3 (TRIB3) OTG5OS7X TRIB3_HUMAN Increases Expression [23]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 (PLCB1) OT9HYT7A PLCB1_HUMAN Increases Expression [35]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) OT0DZGY4 E2AK3_HUMAN Increases Phosphorylation [12]
Long-chain-fatty-acid--CoA ligase 6 (ACSL6) OT0TT8P8 ACSL6_HUMAN Affects Response To Substance [14]
Mu-type opioid receptor (OPRM1) OT16AAT8 OPRM_HUMAN Increases Response To Substance [36]
Flavin-containing monooxygenase 3 (FMO3) OT1G2EV3 FMO3_HUMAN Increases Metabolism [37]
3',5'-cyclic-AMP phosphodiesterase 4D (PDE4D) OT1RWFV0 PDE4D_HUMAN Affects Response To Substance [14]
Coiled-coil alpha-helical rod protein 1 (CCHCR1) OT22C116 CCHCR_HUMAN Affects Response To Substance [14]
5-hydroxytryptamine receptor 1A (HTR1A) OT38K9MK 5HT1A_HUMAN Increases Response To Substance [38]
Sodium-dependent dopamine transporter (SLC6A3) OT39XG28 SC6A3_HUMAN Increases Response To Substance [39]
Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 2 (LINGO2) OT3N88Q1 LIGO2_HUMAN Affects Response To Substance [14]
Rap guanine nucleotide exchange factor 5 (RAPGEF5) OT53VS75 RPGF5_HUMAN Affects Response To Substance [14]
Cubilin (CUBN) OT5A9HD3 CUBN_HUMAN Affects Response To Substance [14]
Regulator of G-protein signaling 17 (RGS17) OT5RVUDS RGS17_HUMAN Affects Response To Substance [14]
Dual specificity mitogen-activated protein kinase kinase 5 (MAP2K5) OT6T408U MP2K5_HUMAN Affects Response To Substance [14]
RNA-binding protein Raly (RALY) OT78NNWY RALY_HUMAN Affects Response To Substance [14]
Collagen alpha-1(XXVIII) chain (COL28A1) OT78UJD5 COSA1_HUMAN Affects Response To Substance [14]
FK506-binding protein 15 (FKBP15) OT7NQJAU FKB15_HUMAN Affects Response To Substance [14]
Mitochondrial amidoxime reducing component 2 (MTARC2) OT8B6LVD MARC2_HUMAN Affects Response To Substance [14]
5-hydroxytryptamine receptor 6 (HTR6) OT8GTDDY 5HT6R_HUMAN Increases Response To Substance [40]
PR domain zinc finger protein 2 (PRDM2) OT8L7CGX PRDM2_HUMAN Affects Response To Substance [14]
D(4) dopamine receptor (DRD4) OTAJTO7N DRD4_HUMAN Increases Response To Substance [41]
Unconventional myosin-Vb (MYO5B) OTCKL3W3 MYO5B_HUMAN Affects Response To Substance [14]
Cadherin-13 (CDH13) OTD2CYM5 CAD13_HUMAN Affects Response To Substance [14]
POU domain, class 5, transcription factor 1 (POU5F1) OTDHHN7O PO5F1_HUMAN Affects Response To Substance [14]
Transient receptor potential cation channel subfamily M member 3 (TRPM3) OTE4CDOQ TRPM3_HUMAN Affects Response To Substance [14]
Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha' (PDE6C) OTE7EVWQ PDE6C_HUMAN Affects Response To Substance [14]
Proenkephalin-B (PDYN) OTEJ6430 PDYN_HUMAN Increases Response To Substance [42]
Astrotactin-2 (ASTN2) OTF0W2FJ ASTN2_HUMAN Affects Response To Substance [14]
Dendritic cell-specific transmembrane protein (DCSTAMP) OTFKRP2H DCSTP_HUMAN Affects Response To Substance [14]
Gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2) OTGNDWUO GBRG2_HUMAN Increases Response To Substance [43]
Bis(5'-adenosyl)-triphosphatase (FHIT) OTGWBSLA FHIT_HUMAN Affects Response To Substance [14]
CUB and sushi domain-containing protein 1 (CSMD1) OTIVDSC4 CSMD1_HUMAN Affects Response To Substance [14]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Increases Response To Substance [44]
E3 ubiquitin-protein ligase SH3RF3 (SH3RF3) OTK9VVUU SH3R3_HUMAN Affects Response To Substance [14]
Mitochondrial amidoxime-reducing component 1 (MTARC1) OTNBE033 MARC1_HUMAN Affects Response To Substance [14]
Heparan sulfate glucosamine 3-O-sulfotransferase 4 (HS3ST4) OTO0UBFN HS3S4_HUMAN Affects Response To Substance [14]
3',5'-cyclic-AMP phosphodiesterase 4B (PDE4B) OTOA8WU2 PDE4B_HUMAN Affects Response To Substance [14]
Acyloxyacyl hydrolase (AOAH) OTOYBXKW AOAH_HUMAN Affects Response To Substance [14]
cGMP-dependent protein kinase 1 (PRKG1) OTPAS4LF KGP1_HUMAN Affects Response To Substance [14]
Alpha-synuclein (SNCA) OTPWC1MR SYUA_HUMAN Increases Response To Substance [45]
Procollagen C-endopeptidase enhancer 2 (PCOLCE2) OTSUEQZ1 PCOC2_HUMAN Affects Response To Substance [14]
Adenylate kinase isoenzyme 5 (AK5) OTTGXLOT KAD5_HUMAN Affects Response To Substance [14]
PH and SEC7 domain-containing protein 3 (PSD3) OTTN9B9O PSD3_HUMAN Affects Response To Substance [14]
Plasma serine protease inhibitor (SERPINA5) OTTZXPGD IPSP_HUMAN Affects Response To Substance [14]
Xylosyl- and glucuronyltransferase LARGE1 (LARGE1) OTUH7H9F LARG1_HUMAN Affects Response To Substance [14]
Adenosine receptor A2a (ADORA2A) OTVRBZ0I AA2AR_HUMAN Increases Response To Substance [46]
Pro-neuregulin-1, membrane-bound isoform (NRG1) OTZO6F1X NRG1_HUMAN Affects Response To Substance [14]
------------------------------------------------------------------------------------
⏷ Show the Full List of 108 DOT(s)

References

1 ClinicalTrials.gov (NCT04614584) Mirtazapine and Methamphetamine Drug-drug Interaction Study
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7241).
3 Methamphetamine FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4803).
5 Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
6 Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
7 A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64.
8 Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol. 2004 Dec;24(6):647-52.
9 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
10 Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neurosci Lett. 2006 Mar 13;395(3):185-90. doi: 10.1016/j.neulet.2005.10.096. Epub 2005 Dec 1.
11 Effects of different antipsychotics and the antidepressant mirtazapine on glucose transporter mRNA levels in human blood cells. J Psychiatr Res. 2006 Jun;40(4):374-9. doi: 10.1016/j.jpsychires.2005.04.016. Epub 2005 Jul 5.
12 Methamphetamine-mediated endoplasmic reticulum (ER) stress induces type-1 programmed cell death in astrocytes via ATF6, IRE1 and PERK pathways. Oncotarget. 2016 Jul 19;7(29):46100-46119. doi: 10.18632/oncotarget.10025.
13 Thioredoxin-1 blocks methamphetamine-induced injury in brain through inhibiting endoplasmic reticulum and mitochondria-mediated apoptosis in mice. Neurotoxicology. 2020 May;78:163-169. doi: 10.1016/j.neuro.2020.03.006. Epub 2020 Mar 20.
14 Genome-wide association for methamphetamine dependence: convergent results from 2 samples. Arch Gen Psychiatry. 2008 Mar;65(3):345-55. doi: 10.1001/archpsyc.65.3.345.
15 Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend. 2009 Jan 1;99(1-3):231-9.
16 Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter. J Med Chem. 2018 Oct 25;61(20):9121-9131.
17 Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics. 2001 Aug;11(6):477-87.
18 A preliminary study: novelty seeking, frontal executive function, and dopamine receptor (D2) TaqI A gene polymorphism in patients with methamphetamine dependence. Compr Psychiatry. 2008 Jul-Aug;49(4):387-92. doi: 10.1016/j.comppsych.2008.01.008. Epub 2008 Mar 21.
19 Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis. Am J Psychiatry. 2007 Jul;164(7):1105-14. doi: 10.1176/ajp.2007.164.7.1105.
20 Evidence for shared genetic risk between methamphetamine-induced psychosis and schizophrenia. Neuropsychopharmacology. 2013 Sep;38(10):1864-70. doi: 10.1038/npp.2013.94. Epub 2013 Apr 12.
21 Methamphetamine alters the normal progression by inducing cell cycle arrest in astrocytes. PLoS One. 2014 Oct 7;9(10):e109603.
22 An insight into the hepatocellular death induced by amphetamines, individually and in combination: the involvement of necrosis and apoptosis. Arch Toxicol. 2013 Dec;87(12):2165-85. doi: 10.1007/s00204-013-1082-9. Epub 2013 Jul 3.
23 Involvement of C/EBP-related signaling pathway in methamphetamine-induced neuronal autophagy and apoptosis. Toxicol Lett. 2019 Sep 15;312:11-21. doi: 10.1016/j.toxlet.2019.05.003. Epub 2019 May 3.
24 CDK5-mediated tau accumulation triggers methamphetamine-induced neuronal apoptosis via endoplasmic reticulum-associated degradation pathway. Toxicol Lett. 2018 Aug;292:97-107. doi: 10.1016/j.toxlet.2018.04.027. Epub 2018 Apr 26.
25 Methamphetamine exposure upregulates the amyloid precursor protein and hyperphosphorylated tau expression: The roles of insulin signaling in SH-SY5Y cell line. J Toxicol Sci. 2019;44(7):493-503. doi: 10.2131/jts.44.493.
26 Methamphetamine induces AP-1 and NF-kappaB binding and transactivation in human brain endothelial cells. J Neurosci Res. 2001 Nov 15;66(4):583-91. doi: 10.1002/jnr.1248.
27 Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):467-74. doi: 10.1097/00126334-200312150-00004.
28 Role of PUMA in methamphetamine-induced neuronal apoptosis. Toxicol Lett. 2016 Jan 5;240(1):149-60. doi: 10.1016/j.toxlet.2015.10.020. Epub 2015 Oct 30.
29 Methamphetamine-induced myocardial infarction with elevated troponin I. Am J Emerg Med. 2006 Jan;24(1):132-4. doi: 10.1016/j.ajem.2005.08.005.
30 Dopamine D1 receptor protein is elevated in nucleus accumbens of human, chronic methamphetamine users. Mol Psychiatry. 2000 Nov;5(6):664-72. doi: 10.1038/sj.mp.4000760.
31 Microglial and astrocytic changes in the striatum of methamphetamine abusers. Leg Med (Tokyo). 2010 Mar;12(2):57-62. doi: 10.1016/j.legalmed.2009.11.001. Epub 2010 Jan 27.
32 Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry. 2006 Jan;63(1):90-100. doi: 10.1001/archpsyc.63.1.90.
33 Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci. 2009 Nov 25;29(47):14734-40. doi: 10.1523/JNEUROSCI.3765-09.2009.
34 Melatonin attenuates methamphetamine-induced neuroinflammation through the melatonin receptor in the SH-SY5Y cell line. Neurotoxicology. 2015 Sep;50:122-30. doi: 10.1016/j.neuro.2015.08.008. Epub 2015 Aug 15.
35 Inhibition of PLC1 signaling pathway regulates methamphetamine self-administration and neurotoxicity in rats. Food Chem Toxicol. 2021 Mar;149:111970. doi: 10.1016/j.fct.2021.111970. Epub 2021 Jan 7.
36 Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms. Pharmacogenomics J. 2006 May-Jun;6(3):179-88. doi: 10.1038/sj.tpj.6500355.
37 What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse?. Toxicol Lett. 2016 Sep 6;258:55-70. doi: 10.1016/j.toxlet.2016.06.013. Epub 2016 Jun 15.
38 Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients. Neuropharmacology. 2010 Feb;58(2):452-6. doi: 10.1016/j.neuropharm.2009.09.006. Epub 2009 Sep 10.
39 Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenomics J. 2003;3(4):242-7. doi: 10.1038/sj.tpj.6500189.
40 Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population. Drug Alcohol Depend. 2011 Jan 1;113(1):1-7. doi: 10.1016/j.drugalcdep.2010.06.021. Epub 2010 Aug 11.
41 Association analysis of the DRD4 and COMT genes in methamphetamine abuse. Am J Med Genet B Neuropsychiatr Genet. 2004 Aug 15;129B(1):120-4. doi: 10.1002/ajmg.b.30024.
42 Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence. Neurosci Lett. 2006 May 29;400(1-2):158-62. doi: 10.1016/j.neulet.2006.02.038. Epub 2006 Mar 9.
43 Haplotype association between GABAA receptor gamma2 subunit gene (GABRG2) and methamphetamine use disorder. Pharmacogenomics J. 2005;5(2):89-95. doi: 10.1038/sj.tpj.6500292.
44 Association analysis of SOD2 variants with methamphetamine psychosis in Japanese and Taiwanese populations. Hum Genet. 2006 Sep;120(2):243-52. doi: 10.1007/s00439-006-0189-y. Epub 2006 Jun 29.
45 Study of association between alpha-synuclein gene polymorphism and methamphetamine psychosis/dependence. Ann N Y Acad Sci. 2004 Oct;1025:325-34. doi: 10.1196/annals.1316.040.
46 The adenosine A2A receptor is associated with methamphetamine dependence/psychosis in the Japanese population. Behav Brain Funct. 2010 Aug 30;6:50. doi: 10.1186/1744-9081-6-50.